Living Models

Executive Summary

Living Models is a Paris-based biotech startup founded in 2020 that leverages machine learning to create dynamic, predictive models of biological systems, with a focus on optimizing drug delivery for oncology and infectious diseases. By simulating how therapeutics interact with complex human physiology, the company aims to enhance precision medicine and improve treatment efficacy. Despite being in the platform stage with no disclosed funding or valuation, Living Models has positioned itself at the intersection of AI and drug delivery, a rapidly growing field attracting significant pharma interest. The company's early-stage status and lack of publicly available milestones suggest it is still developing its core technology and seeking proof-of-concept validation. However, its focus on AI-driven simulation could offer a competitive edge in reducing drug development costs and timelines, making it an intriguing but high-risk opportunity. The main risks include technical validation, competition from established AI drug discovery platforms, and the need for substantial capital to advance its models into clinical applications.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Pharmaceutical Partnership or Licensing Deal50% success
• Q2 2026Publication of Preclinical Validation Data80% success